164 related articles for article (PubMed ID: 24704786)
1. Structural basis of recognition of interferon-α receptor by tyrosine kinase 2.
Wallweber HJ; Tam C; Franke Y; Starovasnik MA; Lupardus PJ
Nat Struct Mol Biol; 2014 May; 21(5):443-8. PubMed ID: 24704786
[TBL] [Abstract][Full Text] [Related]
2. Community analysis of large-scale molecular dynamics simulations elucidated dynamics-driven allostery in tyrosine kinase 2.
Lesgidou N; Vlassi M
Proteins; 2024 Apr; 92(4):474-498. PubMed ID: 37950407
[TBL] [Abstract][Full Text] [Related]
3. Cytokine signaling: birth of a pathway.
O'Shea JJ; Gadina M; Kanno Y
J Immunol; 2011 Dec; 187(11):5475-8. PubMed ID: 22102730
[No Abstract] [Full Text] [Related]
4. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
[TBL] [Abstract][Full Text] [Related]
5. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
6. The Structural Basis for Class II Cytokine Receptor Recognition by JAK1.
Ferrao R; Wallweber HJ; Ho H; Tam C; Franke Y; Quinn J; Lupardus PJ
Structure; 2016 Jun; 24(6):897-905. PubMed ID: 27133025
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor.
Brooks AJ; Dai W; O'Mara ML; Abankwa D; Chhabra Y; Pelekanos RA; Gardon O; Tunny KA; Blucher KM; Morton CJ; Parker MW; Sierecki E; Gambin Y; Gomez GA; Alexandrov K; Wilson IA; Doxastakis M; Mark AE; Waters MJ
Science; 2014 May; 344(6185):1249783. PubMed ID: 24833397
[TBL] [Abstract][Full Text] [Related]
9. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
10. Designer proteins to trigger cell death.
Fairbrother WJ; Ashkenazi A
Cell; 2014 Jun; 157(7):1506-8. PubMed ID: 24949963
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase.
Gauzzi MC; Velazquez L; McKendry R; Mogensen KE; Fellous M; Pellegrini S
J Biol Chem; 1996 Aug; 271(34):20494-500. PubMed ID: 8702790
[TBL] [Abstract][Full Text] [Related]
12. The molecular details of cytokine signaling via the JAK/STAT pathway.
Morris R; Kershaw NJ; Babon JJ
Protein Sci; 2018 Dec; 27(12):1984-2009. PubMed ID: 30267440
[TBL] [Abstract][Full Text] [Related]
13. The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions.
Ferrao R; Lupardus PJ
Front Endocrinol (Lausanne); 2017; 8():71. PubMed ID: 28458652
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and consequences of Jak-STAT signaling in the immune system.
Villarino AV; Kanno Y; O'Shea JJ
Nat Immunol; 2017 Mar; 18(4):374-384. PubMed ID: 28323260
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of IFNAR2 and TYK2 transcripts' prognostic role in COVID-19 patients: a retrospective study.
Razavi A; Raei M; Hatami Y; Chokami GS; Goudarzi Y; Ghasemian R; Alizadeh-Navaei R; Yarmohammadi H; Soltanipur M; Tabarestani M; Valadan R; Meshkinfam Haghighi F; Tarsi AK; Razavi B
Front Cell Infect Microbiol; 2024; 14():1356542. PubMed ID: 38741892
[TBL] [Abstract][Full Text] [Related]
16. Structure-function of type I and III interferons.
de Weerd NA; Kurowska AK; Mendoza JL; Schreiber G
Curr Opin Immunol; 2024 Feb; 86():102413. PubMed ID: 38608537
[TBL] [Abstract][Full Text] [Related]
17. JAK/STAT3 signaling in cardiac fibrosis: a promising therapeutic target.
Jiang H; Yang J; Li T; Wang X; Fan Z; Ye Q; Du Y
Front Pharmacol; 2024; 15():1336102. PubMed ID: 38495094
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
[TBL] [Abstract][Full Text] [Related]
19. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
Wang J; Batista VS; Bunick CG
bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
[TBL] [Abstract][Full Text] [Related]
20. Tick-borne flavivirus NS5 antagonizes interferon signaling by inhibiting the catalytic activity of TYK2.
Gracias S; Chazal M; Decombe A; Unterfinger Y; Sogues A; Pruvost L; Robert V; Lacour SA; Lemasson M; Sourisseau M; Li Z; Richardson J; Pellegrini S; Decroly E; Caval V; Jouvenet N
EMBO Rep; 2023 Dec; 24(12):e57424. PubMed ID: 37860832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
